Skip to main content
NCBI home page
ACS AuthorChoice logoLink to ACS AuthorChoice
. 2014 Jun 4;53(24):4034–4046. doi: 10.1021/bi5004102

Early Endosomal Escape of a Cyclic Cell-Penetrating Peptide Allows Effective Cytosolic Cargo Delivery

Ziqing Qian †, Jonathan R LaRochelle ‡, Bisheng Jiang †, Wenlong Lian †, Ryan L Hard †, Nicholas G Selner †, Rinrada Luechapanichkul †, Amy M Barrios §, Dehua Pei †,*
PMCID: PMC4075989  PMID: 24896852

Abstract

graphic file with name bi-2014-004102_0008.jpg

Cyclic heptapeptide cyclo(FΦRRRRQ) (cFΦR4, where Φ is l-2-naphthylalanine) was recently found to be efficiently internalized by mammalian cells. In this study, its mechanism of internalization was investigated by perturbing various endocytic events through the introduction of pharmacologic agents and genetic mutations. The results show that cFΦR4 binds directly to membrane phospholipids, is internalized into human cancer cells through endocytosis, and escapes from early endosomes into the cytoplasm. Its cargo capacity was examined with a wide variety of molecules, including small-molecule dyes, linear and cyclic peptides of various charged states, and proteins. Depending on the nature of the cargos, they may be delivered by endocyclic (insertion of cargo into the cFΦR4 ring), exocyclic (attachment of cargo to the Gln side chain), or bicyclic approaches (fusion of cFΦR4 and cyclic cargo rings). The overall delivery efficiency (i.e., delivery of cargo into the cytoplasm and nucleus) of cFΦR4 was 4–12-fold higher than those of nonaarginine, HIV Tat-derived peptide, or penetratin. The higher delivery efficiency, coupled with superior serum stability, minimal toxicity, and synthetic accessibility, renders cFΦR4 a useful transporter for intracellular cargo delivery and a suitable system for investigating the mechanism of endosomal escape.

The plasma membrane presents a major challenge in drug discovery, especially for biologics such as peptides, proteins, and nucleic acids. One potential strategy for subverting the membrane barrier and delivering the biologics into cells is to attach them to “cell-penetrating peptides” (CPPs). Since the initial observation that HIV trans-activator of transcription, Tat, internalizes into mammalian cells and activates viral replication in the late 1980s,1,2 a large number of CPPs consisting of 6–20 residues have been reported.3−8 CPPs have been used to deliver small-molecule drugs,9,10 DNA,11,12 RNA,13−16 proteins,17−19 and nanoparticles20−22 into mammalian cells and tissues through either covalent attachment or electrostatic association. Many CPPs display minimal toxicity and immunogenicity at physiologically relevant concentrations,23,24 and the incorporation of specific unnatural amino acids25 and other chemical moieties26,27 has been found to increase the stability and extent of cytosolic delivery.

Despite three decades of investigation, the fundamental basis for CPP activity remains elusive. Two distinct and non-mutually exclusive mechanisms have been proposed for the CPPs whose primary sequences are characterized by multiple arginine residues. In the first mechanism (direct membrane translocation), the arginine guanidinium groups interact with phospholipids of the plasma membrane to generate neutral ion pairs that passively diffuse across the membrane28,29 or promote the formation of transient pores that permit the CPPs to traverse the lipid bilayer.30,31 In the second mechanism, CPPs associate with cell surface glycoproteins and membrane phospholipids, internalize into cells through endocytosis,32−36 and subsequently exit from endosomes into the cytoplasm. Taken together, a majority of data show that at low CPP concentrations, cellular uptake occurs mostly through endocytosis, whereas direct membrane translocation becomes prevalent at concentrations above 10 μM.37 However, the mechanism(s) of entry and the efficiency of uptake may vary with CPP identity, cargo, cell type, and other factors.38,39

CPPs that enter cells via endocytosis must exit from endocytic vesicles to reach the cytosol. Unfortunately, the endosomal membrane has proven to be a significant barrier toward cytoplasmic delivery by these CPPs; often a negligible fraction of the peptides escapes into the cell interior.40−42 For example, even in the presence of the fusogenic hemagglutinin peptide HA2, which has been demonstrated to enhance endosomal cargo release, >99% of a Tat–Cre fusion protein remains entrapped in macropinosomes 24 h after initial uptake.35 Recently, two new types of CPPs with improved endosomal escape efficiencies have been discovered. Appelbaum et al. showed that folded miniature proteins containing a discrete pentaarginine motif were able to effectively overcome endosomal entrapment and reach the cytosol of mammalian cells.42 This motif consists of five arginines across three turns of an α-helix, and proteins containing this motif were released from early (Rab5+) endosomes into the cell interior. We and others found that cyclization of certain arginine-rich CPPs enhances their cellular uptake.43−46 Small amphipathic cyclic peptides such as cyclo(FΦRRRRQ) (cFΦR4, where Φ is l-2-naphthylalanine) are internalized by mammalian cells in an energy-dependent manner and enter the cytoplasm and nucleus with efficiencies 2–5-fold higher than that of nonaarginine (R9).43 Moreover, membrane impermeable cargos such as phosphopeptides can be inserted into the cFΦR4 ring, resulting in their delivery into the cytoplasm of target cells. However, insertion of a cargo into the cyclic peptide ring, which we term the “endocyclic” delivery method (Figure 1A), is limited to relatively short peptides (no more than seven amino acids), as large rings, for yet unknown reasons, display poor internalization efficiency.43

Figure 1.

Figure 1

Open in a new tab

Structures showing cargo attachment during endocyclic (A), exocyclic (B), and bicyclic (C) delivery of cargos (colored red) by cFΦR4.

To gain insight into the cFΦR4 mechanism of action and potentially design cyclic CPPs of still higher efficiency, in this study we investigated the internalization mechanism of cFΦR4 through the use of artificial membranes and pharmacologic agents as well as genetic mutations that perturb various endocytic events. Our data show that cFΦR4 binds directly to the plasma membrane phospholipids and enters cells through endocytosis. Like the miniature proteins displaying the pentaarginine motif,42 cFΦR4 escapes from the early endosomes into the cytosol. We also examined the ability of cFΦR4 to deliver a wide range of cargo molecules, including linear peptides of varying charges, cyclic peptides, and large proteins, into the cytoplasm of mammalian cells by exocyclic [attachment of cargo to the Gln side chain (Figure 1B)] or bicyclic [fusion of the cFΦR4 and cyclic cargo rings (Figure 1C)] delivery methods. We found that cFΦR4 is remarkably tolerant to the size and nature of cargos and efficiently transported all of the cargos tested into the cytoplasm and nucleus of mammalian cells. In addition, cFΦR4 exhibits superior stability against proteolysis over linear CPPs but minimal cytotoxicity. cFΦR4 therefore provides a practically useful transporter for cytosolic cargo delivery as well as a system for investigating the mechanism of early endosomal cargo release.

Materials and Methods

Materials

Reagents for peptide synthesis were purchased from Advanced ChemTech (Louisville, KY), NovaBiochem (La Jolla, CA), or Anaspec (San Jose, CA). 2,2′-Dipyridyl disulfide, Lissamine rhodamine B sulfonyl chloride, fluorescein isothiocyanate (FITC), dexamethasone (Dex), coenzyme A trilithium salt, FITC-labeled dextran (dextranFITC), and human serum were purchased from Sigma-Aldrich (St. Louis, MO). Cell culture media, fetal bovine serum (FBS), penicillin/streptomycin, 0.25% trypsin-ethylenediaminetetraacetic acid, Hoescht 33342, Alexa488-labeled dextran (dextranAlexa488), Dulbecco’s phosphate-buffered saline (DPBS) (2.67 mM potassium chloride, 1.47 mM potassium phosphate monobasic, 137 mM sodium chloride, and 8.06 mM sodium phosphate dibasic), and Lipofectamine 2000 were purchased from Invitrogen (Carlsbad, CA). PD-10 desalting columns were purchased from GE-Healthcare (Piscataway, NJ). Nuclear staining dye DRAQ5 was purchased from Thermo Scientific (Rockford, IL), while the cell proliferation kit [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)] was purchased from Roche (Indianapolis, IN). The anti-phosphotyrosine (pY) antibody (clone 4G10) was purchased from Millipore (Temecula, CA).

Peptide Synthesis and Labeling

The details of peptide synthesis are described in the Supporting Information. Peptide labeling with FITC was performed by dissolving the purified peptide (∼1 mg) in 300 μL of 1:1:1 (v/v) dimethyl sulfoxide (DMSO)/dimethylformamide (DMF)/150 mM sodium bicarbonate (pH 8.5) mixture and mixing that solution with 10 μL of FITC in DMSO (100 mg/mL). After 20 min at room temperature, the reaction mixture was subjected to reversed-phase high-performance liquid chromatography (HPLC) on a C18 column to isolate the FITC-labeled peptide. To generate rhodamine- and Dex-labeled peptides (Figure S1 of the Supporting Information), an Nε-4-methoxytrityl-l-lysine was added to the C-terminus. After solid-phase peptide synthesis, the lysine side chain was selectively deprotected using 1% (v/v) trifluoroacetic acid in CH2Cl2. The resin was incubated with Lissamine rhodamine B sulfonyl chloride and DIPEA (5 equiv each) in DMF overnight. The peptides were fully deprotected as described in the Supporting Information, triturated with diethyl ether, and purified by HPLC. The Dex-labeled peptide was produced by incubating the resin with a mixture of dexamethasone-21-thiopropionic acid, HBTU, and DIPEA (5, 5, and 10 equiv, respectively) in DMF for 3 h.42 The peptide was then deprotected, triturated, and purified by HPLC. Bicyclic peptides, phosphocoumaryl aminopropionic acid (pCAP), and pCAP-containing peptides (PCPs) were synthesized as previously described.47−49 The authenticity of each peptide was confirmed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.

Preparation of cFΦR4–Protein Conjugates

Peptide cFΦR4 containing a C-terminal cysteine [cFΦR4-SH, ∼10 μmol (Figure S2 of the Supporting Information)] was dissolved in 1 mL of degassed DPBS and mixed with 2,2′-dipyridyl disulfide (5 equiv) dissolved in acetone (0.5 mL). After 2 h at room temperature, the reaction product cFΦR4-SS-Py was purified by reversed-phase HPLC. The product was incubated with coenzyme A (2 equiv) in DPBS for 2 h. The resulting cFΦR4-SS-CoA adduct was purified again by reversed-phase HPLC. Green fluorescent protein (GFP) containing an N-terminal ybbR tag (VLDSLEFIASKL) and a C-terminal six-histidine tag was expressed in Escherichia coli and purified as previously described.50 Next, ybbR-GFP (30 μM), cFΦR4-SS-CoA (30 μM), and phosphopantetheinyl transferase Sfp (0.5 μM) were mixed in 50 mM HEPES (pH 7.4) and 10 mM MgCl2 (total volume of 1.5 mL) and incubated at 37 °C for 15 min. The labeled protein, cFΦR4-S-S-GFP (Figure S2 of the Supporting Information), was separated from unreacted cFΦR4-SS-CoA by passing the reaction mixture through a PD-10 desalting column. GFP conjugated to Tat (Tat-S-S-GFP) and cFΦR4-conjugated PTP1B (cFΦR4-PTP1B) were prepared in a similar fashion (Figure S3 of the Supporting Information).

Cell Culture and Transfection

HEK293, HeLa, MCF-7, NIH 3T3, and A549 cells were maintained in medium consisting of Dulbecco’s modified Eagle’s medium (DMEM), 10% FBS, and 1% penicillin/streptomycin. H1650 and H1299 cells were grown in RPMI-1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were cultured in a humidified incubator at 37 °C with 5% CO2. For the transfection of HeLa cells, cells were seeded onto a 96-well plate at a density of 10000 cells/well. Following attachment, cells were transfected with plasmids encoding the Rab5-green fluorescent protein fusion (Rab5-GFP, a gift from P. Di Camilli), Rab7-GFP (Addgene plasmid 28047, Q. Zhong), the glucocorticoid receptor (C638G)-GFP fusion (GR-GFP),51 DsRed-Rab5 WT (Addgene plasmid 13050, R. Pagano), or DsRed-Rab5Q79L (Addgene plasmid 29688, E. DeRobertis) following manufacturer’s protocols for Lipofectamine 2000.

Confocal Microscopy

To examine the colocalization between rhodamine-labeled cyclic peptide (cFΦR4Rho) and Rab5+ or Rab7+ endosomes, HeLa cells transfected with Rab5-GFP or Rab7-GFP were plated (200 μL, 104 cells/well, 96-well glass bottom MatriPlates) the day prior to the experiment. On the day of the experiment, HeLa cells were treated with 1 μM cFΦR4Rho in DMEM supplemented with 300 nM Hoescht 33342 for 30 min. After that, the cells were washed with HKR buffer [10 mM HEPES (pH 7.4), 140 mM NaCl, 2 mM KCl, 1 mM CaCl2, and 1 mM MgCl2] and imaged using a PerkinElmer LiveView spinning disk confocal microscope.

For the GR translocation assay, HeLa cells transfected with GR-GFP were plated as described above.51 The cells were treated for 30 min with DMEM containing 1 μM Dex or Dex-peptide conjugate and 300 nM Hoescht 33342 and imaged using a Zeiss Axiovert 200M epifluorescence microscope outfitted with a Ziess Axiocam mRM camera and an EXFO-Excite series 120 Hg arc lamp. The translocation ratio (the ratio of mean GFP intensity in the nuclear and surrounding regions) for individual cells was measured as described in the Supporting Information. To examine the effect of endocytosis inhibitors, transfected HeLa cells were pretreated for 30 min with clear DMEM containing the inhibitors before incubation with Dex or Dex-peptide conjugates. To test whether Rab5 activity is required for endosomal escape, HeLa cells were transfected with GR-GFP and DsRed-Rab5 WT or DsRed-Rab5Q79L before being treated with Dex or the Dex-peptide conjugate and imaged as described above.42

To examine the internalization of rhodamine-labeled peptides, 5 × 104 HEK293 cells were plated in a 35 mm glass-bottom microwell dish (MatTek). On the day of the experiment, the cells were incubated with the peptide solution (5 μM) and 0.5 mg/mL dextranFITC at 37 °C for 2 h. The cells were gently washed with DPBS twice and imaged on a Visitech Infinity 3 Hawk 2D-array live cell imaging confocal microscope. To detect the internalization of pCAP-containing peptides, HEK293 cells were similarly plated and incubated with the peptide solution (5 μM) at 37 °C for 60 min. After removal of the medium, the cells were gently washed with DPBS containing sodium pervanadate (1 mM) twice and incubated for 10 min in DPBS containing 5 μM nuclear staining dye DRAQ5. The resulting cells were washed with DPBS twice and imaged on a spinning disk confocal microscope (UltraView Vox CSUX1 system). To monitor GFP internalization, 5 × 104 HEK293 cells were seeded in a 35 mm glass-bottom microwell dish and cultured overnight. Cells were treated with CPP-S-S-GFP (1 μM) at 37 °C for 2 h. After removal of the medium, the cells were incubated in DPBS containing 5 μM DRAQ5 for 10 min. The cells were washed with DPBS twice and imaged on a Visitech Infinity 3 Hawk 2D-array live cell imaging confocal microscope.

Flow Cytometry

To quantify the delivery efficiencies of pCAP-containing peptides, HeLa cells were cultured in six-well plates (5 × 105 cells per well) for 24 h. On the day of the experiment, the cells were incubated with 10 μM pCAP-containing peptide in clear DMEM with 1% FBS at 37 °C for 2 h. The cells were washed with DPBS containing 1 mM sodium pervanadate, detached from plate with 0.25% trypsin, suspended in DPBS containing 1% bovine serum albumin, and analyzed on a BD FACS Aria flow cytometer with excitation at 355 nm. Data were analyzed with Flowjo (Tree Star) The experimental procedure for estimating the effect of the cyclic peptide on endocytosis is described in the Supporting Information.

Immunoblotting

NIH 3T3 cells were cultured in full growth medium to reach 80% confluence. The cells were starved in serum free medium for 3 h and treated with different concentrations of cFΦR4-PTP1B or untagged PTP1B for 2 h, followed by a 30 min incubation in medium supplemented with 1 mM sodium pervanadate. The solutions were removed and the cells washed twice with cold DPBS. The cells were detached and lysed in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 10 mM sodium pyrophosphate, 5 mM iodoacetic acid, 10 mM NaF, 1 mM ethylenediaminetetraacetic acid, 2 mM sodium pervanadate, 0.1 mg/mL phenylmethanesulfonyl fluoride, 1 mM benzamidine, and 0.1 mg/mL trypsin inhibitor. After being incubated on ice for 30 min, the cell lysate was centrifuged at 15000 rpm for 25 min in a microcentrifuge. The total cellular proteins were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) and transferred electrophoretically to a polyvinylidene fluoride membrane, which was immunoblotted using anti-pY antibody 4G10.

Results and Discussion

cFΦR4 Enters Cells via Endocytosis

We previously observed that cFΦR4 fails to enter cells at 4 °C or in the presence of sodium azide, suggesting that energy-dependent endocytic processes mediate its cell entry.43 However, other cyclic CPPs have been reported to enter cells by direct membrane translocation.44,45 To further test the role of endocytosis and intracellular trafficking during the cellular uptake of cFΦR4, we examined the extent of colocalization between cFΦR4Rho (Table 1, compound 1) and GFP-tagged Rab proteins that have been demonstrated to localize to vesicles of the endocytic system. Rab5 is a small Rab family GTPase that is primarily localized to early endosomal membranes, whereas Rab7 is predominantly localized to the membranes of late endosomes.52,53 HeLa cells overexpressing GFP-Rab5 or GFP-Rab7 were incubated with 1 μM cFΦR4Rho for 30 min and examined by spinning-disk confocal microscopy (Figure 2A). A large fraction of rhodamine B fluorescence overlapped with that of Rab5-GFP (RGFP,rhodamine = 0.703) and Rab7-GFP (RGFP,rhodamine = 0.591), indicating that cFΦR4Rho is present in both early (Rab5+) and late (Rab7+) endosomes.

Table 1. Sequences of Peptides Used in This Work.

peptide abbreviation peptide sequencea
1 cFΦR4Rho cyclo(FΦRRRRQ)-K(Rho)-NH2
2 cFΦR4Dex cyclo(FΦRRRRQ)-K(Dex)-NH2
3 TatDex H-K(Dex)-GRKKRRQRRRPPQY-NH2
4 cFΦR4FITC cyclo(FΦRRRRQ)-K(FITC)-NH2
5 cFΦR4-R5 cyclo(FΦRRRRQ)-RRRRR-K(Rho)-NH2
6 cFΦR4-A5 cyclo(FΦRRRRQ)-AAAAA-K(Rho)-NH2
7 cFΦR4-F4 cyclo(FΦRRRRQ)-FFFF-K(Rho)-NH2
8 cFΦR4-PCP cyclo(FΦRRRRQ)-miniPEG-DE(pCAP)LI-NH2
9 PCP Ac-DE(pCAP)LI-NH2
10 R9-PCP Ac-RRRRRRRRR-miniPEG-DE(pCAP)LI-NH2
11 Tat-PCP Ac-RKKRRQRRR-miniPEG-DE(pCAP)LI-NH2
12 Antp-PCP Ac-RQIKIWFQNRRMKWKK-miniPEG-DE(pCAP)LI-NH2
13 bicyclo(FΦR4-A5)Rho [Tm(AAAAA)K(RRRRΦF)J]-K(Rho)-NH2
14 bicyclo(FΦR4-A7)Rho [Tm(AAAAAAA)K(RRRRΦF)J]-K(Rho)-NH2
15 bicyclo(FΦR4-RARAR)Rho [Tm(RARAR)K(RRRRΦF)J]-K(Rho)-NH2
16 bicyclo(FΦR4-DADAD)Rho [Tm(DADAD)K(RRRRΦF)J]-K(Rho)-NH2
17 monocyclo(FΦR4-A5)Rho cyclo(AAAAARRRRΦF)-K(Rho)-NH2
18 monocyclo(FΦR4-A7)Rho cyclo(AAAAAAARRRRΦF)-K(Rho)-NH2
19 cFΦR4 cyclo(FΦRRRRQ)
20 R9 H-RRRRRRRRR-OH
21 Tat H-YGRKKRRQRRR-OH
22 Antp H-RQIKIWFQNRRMKWKK-OH
Open in a new tab
a

Abbreviations: Φ, l-2-naphthylalanine; J, l-2,3-diaminopropionic acid; Rho, rhodamine B; Dex, dexamethasone; FITC, fluorescein isothiocyanate; miniPEG, 8-amino-3,6-dioxaoctanoic acid; pCAP, phosphocoumaryl aminopropionic acid; Tm, trimesoyl.

Figure 2.

Figure 2

Open in a new tab

cFΦR4 enters cells through endocytosis, localizes to Rab5+ and Rab7+ endosomes, and releases from early endosomes into cytoplasm. (A) Colocalization between Rab5-GFP (left) or Rab7-GFP (right) and cFΦR4Rho (red) HeLa cells stained with Hoescht 33342 (blue). (B) Translocation of GR-GFP after treatment with 1 μM Dex or cFΦR4Dex in the presence and absence of 80 μM Dynasore (Dyna), 50 μM N-ethyl-isopropyl-amiloride (EIPA), 5 mM methyl-β-cyclodextrin (MBCD), 200 nM wortmannin (Wort), or 200 nM bafilomycin (Baf). (C) Translocation of GR-GFP after treatment with 1 μM Dex or cFΦR4Dex upon overexpression of WT Rab5 or Rab5(Q79L). *p ≤ 0.01; **p ≤ 0.001; ns, not significant (two-tailed t test).

To further delineate the endocytic events required for the cytosolic delivery of cFΦR4, we made use of a novel GR-GFP translocation assay42,51,54 and examined the effects of various endocytic inhibitors on the cytosolic delivery of Dex-labeled peptides cFΦR4Dex and TatDex (Figure S1 of the Supporting Information and Table 1, compounds 2 and 3). In resting cells, GR (glucocorticoid receptor) is maintained in the cytoplasm through interactions with host chaperones.55 Upon cytoplasmic delivery of Dex or Dex-peptide conjugates, association with the GR activates translocation from the cytoplasm into the nucleus.56 Thus, the ratio of GR-GFP fluorescence intensity in the nucleus to that in the cytoplasm, or the translocation ratio (TR), provides a semiquantitation of the cytosolic Dex or Dex-peptide concentration. It should be noted that this assay is ideal for comparing the cytosolic concentrations of a Dex derivative under different conditions (e.g., in the absence and presence of an endocytosis inhibitor); for different Dex derivatives (e.g., cFΦR4Dex and TatDex), the TR may also be affected by their solubility, metabolic stability, and/or binding affinity for GR.42,51 Incubation of HeLa cells expressing a GR-GFP fusion protein with 1 μM cFΦR4Dex increased the TR from 1.17 ± 0.23 in untreated cells to 3.50 ± 0.66, confirming that a significant amount of cFΦR4Dex reached the cytoplasm. Treatment of HeLa cells before and during cFΦR4Dex incubation with the cell-permeable dynamin inhibitor Dynasore (Dyna), the cortical actin remodeling inhibitor N-ethyl-isopropyl-amiloride (EIPA), or the cholesterol-sequestering agent methyl-β-cyclodextrin (MBCD) decreased the cFΦR4Dex TR to 2.35 ± 0.75, 1.86 ± 0.46, and 1.56 ± 0.39, respectively (Figure 2B and Figure S4 of the Supporting Information).57−59 These results strongly support our previous hypothesis that cFΦR4 enters cells predominantly through endocytosis,43 and the inhibition pattern suggests the involvement of multiple endocytic mechanisms during the uptake of cFΦR4.

cFΦR4 Escapes from Early Endosomes into the Cytoplasm

The presence of intense, diffuse fluorescence throughout the cytoplasm and nucleus of cells treated with fluorescently labeled cFΦR4 indicates that cFΦR4 efficiently escapes from the endosome (ref (43) and vide infra). In an attempt to understand why cFΦR4 possesses this unusual property among CPPs, we again made use of the GR-GFP translocation assay to examine the effect of downstream endocytic perturbations on the cytoplasmic delivery of cFΦR4Dex. Pretreatment of HeLa cells with the endosomal vesicular ATPase inhibitor bafilomycin (Baf)60 prior to the addition of cFΦR4Dex decreased the TR to 2.66 ± 0.62, suggesting that endosomal acidification facilitates the release of cFΦR4Dex into the cytoplasm. Blocking the maturation of Rab5+ vesicles by pretreating cells with the phosphatidylinositol 3-kinase inhibitor wortmannin (Wort)61 had an only minor effect on the TR (from 3.50 ± 0.66 to 3.15 ± 0.55), supporting the idea that cFΦR4Dex is released from early Rab5+ endosomes. To further test whether endosomal maturation is required for cytosolic delivery, we overexpressed GTPase-inactive Rab5 mutant, Rab5(Q79L), which halts endosomal maturation at the Rab5+ stage.62 Rab5(Q79L) overexpression significantly reduced the TR for TatDex, which has previously been shown to be released from late endosomes42 but had no effect on either free Dex or cFΦR4Dex (Figure 2C and Figure S5 of the Supporting Information), confirming that cFΦR4 is released from early endosomes into the cytoplasm. Interestingly, miniature proteins containing a pentaarginine motif on an α-helix, another system shown to efficiently escape from the endosome, are also released from the early endosome.42 R9 was previously shown to exit the endocytic pathway after the miniature proteins but prior to Tat.42 It appears that compared to other cationic CPPs, cFΦR4 is less dependent on endosomal acidification for release and thus able to exit from the less acidic early endosomes.

cFΦR4 Binds to Membrane Phospholipids

It was previously observed that incubation of 1 μM FITC-labeled cyclic peptide cFΦR4FITC (Table 1, compound 4) with vesicles containing negatively charged phospholipids [90% phosphatidylcholine (PC) and 10% phosphatidylglycerol (PG)] resulted in quenching of the peptide fluorescence, consistent with direct binding of cFΦR4 to phospholipids.43 To test the potential role of membrane binding during endocytic uptake of CPPs, we prepared SUVs that mimic the outer membrane of mammalian cells (45% PC, 20% phosphatidylethanolamine, 20% sphingomyelin, and 15% cholesterol) and tested them for binding to FITC-labeled cFΦR4, R9, and Tat (each at 100 nM) by a fluorescence polarization (FP) assay. cFΦR4 bound to the neutral SUVs with an EC50 value (lipid concentration at which half of cFΦR4FITC is bound) of 2.1 ± 0.1 mM (Figure 3A). R9 showed much weaker binding to the artificial membrane (EC50 > 10 mM), whereas Tat did not bind at all. We next tested the CPPs for binding to heparan sulfate, which was previously proposed to be the primary binding target of cationic CPPs.36,63−67 As expected, R9 and Tat both bound to heparan sulfate with high affinity, having EC50 values of 144 and 304 nM, respectively (Figure 3B). Under the same condition, cFΦR4 showed no detectable binding to heparan sulfate. Our results are in agreement with the previous observations that nonamphipathic cationic CPPs (e.g., Tat and R9) bind tightly with cell surface proteoglycans (e.g., heparan sulfate) but only weakly with membrane lipids.67 The insufficient number of positive charges of cFΦR4 is likely responsible for its lack of strong electrostatic interaction with heparan sulfate. On the other hand, the amphipathic nature and the more rigid cyclic structure of cFΦR4 should facilitate its binding to neutral lipid membranes. These data, together with the inhibition pattern by various endocytic inhibitors described above, suggest that cFΦR4 binds directly to the plasma membrane phospholipids and is internalized by all of the endocytic mechanisms in a piggyback manner.

Figure 3.

Figure 3

Open in a new tab

Binding of FITC-labeled cFΦR4, R9, and Tat to SUV (A) and heparan sulfate (B).

Intracellular Delivery of Peptidyl Cargos

Because endocyclic delivery by cFΦR4 is limited to a heptapeptide or smaller cargos,43 in this study we tested the ability of cFΦR4 to deliver cargos of varying sizes and physicochemical properties attached to the Gln side chain (Figure 1B, exocyclic delivery). We first covalently attached positively charged (RRRRR), neutral (AAAAA), hydrophobic (FFFF), and negatively charged [DE(pCAP)LI] peptides to cFΦR4 (Table 1, compounds 5–8, respectively). The first three peptides were labeled with rhodamine B at a C-terminal lysine side chain (Figure S1 of the Supporting Information), and their internalization into HEK293 cells was examined by live cell confocal microscopy. Cells incubated for 2 h with 5 μM peptide cFΦR4-A5 (Figure 4A) or cFΦR4-R5 (Figure 4B) showed evidence of both punctate and diffuse fluorescence, with the latter distributed almost uniformly throughout the cell. In contrast, the fluid-phase endocytic marker dextranFITC displayed predominantly punctate fluorescence, indicative of endosomal localization. The diffuse rhodamine fluorescence suggests that a fraction of the peptides reached the cytosol and nucleus of the cells. Co-incubation of cells with cFΦR4 (1 μM) and dextranAlexa488 increased the level of internalization of the endocytic marker by 15% (Figure S6 of the Supporting Information), suggesting that cFΦR4 activates endocytosis in cultured cells. cFΦR4-F4 could not be tested because of its poor aqueous solubility.

Figure 4.

Figure 4

Open in a new tab

Representative live cell confocal images of HEK293 cells treated for 2 h with rhodamine B-labeled peptides and fluid-phase uptake marker dextranFITC. (A) Cells treated with 5 μM cFΦR4-A5 and dextranFITC in the same Z section. (B) Same as panel A but with 5 μM cFΦR4-R5.

Peptide cFΦR4-DE(pCAP)LI [cFΦR4-PCP (Figure S1 of the Supporting Information)] was designed to test the ability of cFΦR4 to deliver negatively charged cargos as well as to compare the cytoplasmic delivery efficiency of cFΦR4 with those of other widely used CPPs such as R9, Tat, and penetratin (Antp). Thus, untagged PCP [Ac-DE(pCap)LI-NH2] and PCP conjugated to R9 (R9-PCP), Tat (Tat-PCP), and Antp (Antp-PCP) (Table 1, compounds 9–12, respectively) were also prepared. Note that cFΦR4-PCP carries a net charge of zero at physiological pH. pCAP is nonfluorescent but, upon entering the cell interior, should be rapidly dephosphorylated by endogenous protein tyrosine phosphatases (PTPs) to produce a fluorescent product, coumaryl aminopropionic acid (CAP, excitation at 355 nm and emission at 450 nm).48,49 When assayed against a PTP panel in vitro, all four CPP-PCP conjugates were efficiently dephosphorylated (Table S1 of the Supporting Information). This assay detects only the CPP cargo inside the cytoplasm and nucleus, where the catalytic domains of all known mammalian PTPs are localized.68 Further, CAP is fluorescent only in its deprotonated state (pKa = 7.8); even if some dephosphorylation occurs inside the endosome (pH 6.5–4.5) or lysosome (pH 4.5), it would contribute little to the total fluorescence (Figure S7 of the Supporting Information). Treatment of HEK293 cells with 5 μM cFΦR4-PCP for 60 min resulted in diffuse blue fluorescence throughout the cell, suggesting that cFΦR4-PCP reached the cell interior, whereas the untagged PCP failed to enter cells under the same condition (Figure 5A). When HEK293 cells were pretreated with the PTP inhibitor sodium pervanadate for 1 h prior to incubation with cFΦR4-PCP (5 μM), the CAP fluorescence in the cells diminished to background levels. HEK293 cells treated with R9-PCP, Antp-PCP, or Tat-PCP under identical conditions showed weak fluorescence, consistent with the poor ability of these peptides to access the cell interior (Figure 5A). To quantify the relative intracellular PCP delivery efficiency, HeLa cells were treated with each peptide and analyzed by fluorescence-activated cell sorting (Figure 5B). cFΦR4-PCP was most efficiently internalized by the HeLa cells, with a mean fluorescence intensity (MFI) of 3510 arbitrary units (AU), whereas R9-PCP, Antp-PCP, Tat-PCP, and untagged PCP produced MFI values of 960, 400, 290, and 30 AU, respectively (Figure 5C). Again, when cells were treated with cFΦR4-PCP in the presence of sodium pervanadate, the amount of CAP fluorescence was reduced to near background levels (70 AU). Thus, cFΦR4 is capable of delivering peptidyl cargos of varying physicochemical properties into the cytoplasm with efficiencies 3.7–12-fold higher than those of R9, Antp, and Tat.

Figure 5.

Figure 5

Open in a new tab

Internalization of pCAP-containing peptides into cultured cells: (I) untagged PCP, (II) cFΦR4-PCP, (III) cFΦR4-PCP and Na3VO4, (IV) R9-PCP, (V) Tat-PCP, and (VI) Antp-PCP. (A) Representative live cell confocal images of HEK293 cells treated with 5 μM peptides. The top panel shows the nuclear stain with DRAQ5 and the bottom panel CAP fluorescence in the same Z section. (B) Flow cytometry of HeLa cells treated with 0 or 10 μM peptides. (C) CAP fluorescence from panel B after subtraction of background fluorescence (untreated cells).

Intracellular Delivery of Cyclic Peptides

In recent years, there has been much interest in cyclic peptides as therapeutic agents and biomedical research tools.69,70 For example, cyclic peptides are effective for inhibition of protein–protein interactions,47,71−73 which are challenging targets for conventional small molecules. A major obstacle in developing cyclic peptide therapeutics is that they are generally impermeable to the cell membrane.74−76 Our attempt to deliver cyclic peptides by cFΦR4 by the endocyclic method had only limited success; an increase in cargo size from one to seven residues led to progressively poorer cellular uptake, likely because the larger, more flexible rings bind more poorly to the cell membrane.43 To overcome this limitation, we explored a bicyclic peptide system, in which one ring contains a CPP motif (e.g., FΦR4) while the other ring consists of peptide sequences specific for the desired targets (Figure 1C). The bicyclic system should in principle be able to accommodate cargos of any size, because the cargo does not change the structure of the CPP ring and should have less impact on its delivery efficiency. The additional rigidity of a bicyclic structure should also improve its metabolic stability as well as the target binding affinity and specificity. The bicyclic peptides were readily synthesized by forming three amide bonds between a trimesoyl scaffold and three amino groups on the corresponding linear peptide [i.e., the N-terminal amine, the side chain of a C-terminal diaminopropionic acid (Dap), and the side chain of a lysine (or ornithine, Dap) imbedded between the CPP and target binding motifs].47 To test the validity of this approach, we chose FΦR4 in the C-terminal ring as the CPP moiety and peptides of different lengths and charges (AAAAA, AAAAAAA, RARAR, and DADAD) as cargo (Table 1, compounds 13–16, respectively). For comparison, we also prepared two monocyclic peptides containing FΦR4 as a transporter and peptides A5 and A7 as cargos (Table 1, compounds 17 and 18, respectively). All of the peptides were labeled at a C-terminal lysine side chain with rhodamine B (Figure S1 of the Supporting Information), and their internalization into HEK293 cells was examined by live cell confocal microscopy. Treatment of cells with 5 μM peptide for 2 h resulted in efficient internalization of all six peptides (Figure 6), although FACS analysis indicated that the uptake of bicyclo(FΦR4-A5)Rho was ∼3-fold more efficient than that of the corresponding monocyclic peptide (compound 17). The intracellular distribution of the internalized peptides was quite different between the bicyclic and monocyclic peptides. While the four bicyclic peptides showed evidence of their presence both in the cytoplasm and nucleus (as indicated by the diffuse rhodamine fluorescence) and in the endosomes (as indicated by the fluorescence puncta), the monocyclic peptides exhibited predominantly punctate fluorescence that overlapped with that of the endocytic marker dextranFITC. In all cases, the endocytic marker displayed only punctate fluorescence, indicating that the endosomes were intact in the cells treated with the peptides. These results indicate that the increased structural rigidity of the bicyclic peptides facilitates both the initial uptake by endocytosis and endosomal release, presumably because of their improved binding to the plasma and endosomal membranes. The bicyclic system may provide a general strategy for intracellular delivery of cyclic and bicyclic peptides.

Figure 6.

Figure 6

Open in a new tab

Representative live cell confocal microscopic images of HEK293 cells treated for 2 h with rhodamine B-labeled peptides (5 μM each) and fluid-phase endocytosis marker dextranFITC (0.5 mg/mL). The red fluorescence of rhodamine B and the green fluorescence of dextranFITC from the same Z section and their merged image are shown in each panel. The enlarged images of a typical cell(s) are shown in each case to show the intracellular distribution of the internalized peptides: (A) cells treated with bicyclo(FΦR4-A5)Rho, (B) cells treated with monocyclo(FΦR4-A5)Rho, (C) cells treated with bicyclo(FΦR4-A7)Rho, (D) cells treated with monocyclo(FΦR4-A7)Rho, (E) cells treated with bicyclo(FΦR4-RARAR)Rho, and (F) cells treated with bicyclo(FΦR4-DADAD)Rho.

Intracellular Delivery of Protein Cargos

To test whether cFΦR4 is capable of transporting full-length proteins into mammalian cells, we chose GFP because of its intrinsic fluorescence and attached cFΦR4 to its N-terminus through a disulfide bond (Figure 7A and Figure S2 of the Supporting Information). The disulfide exchange reaction is highly specific, efficient, and reversible; upon entering the cytoplasm, the CPP-S-S-protein conjugate is expected to be rapidly reduced to release the native protein. Although cFΦR4 can be directly attached to a native or engineered surface cysteine residue(s) on a cargo protein, we employed a GFP variant containing a 12-amino acid ybbR tag at its N-terminus (which was already available in our laboratory) and used phosphopantetheinyl transferase Sfp to enzymatically attach cFΦR4 to the ybbR tag.50 This permitted the attachment of a single cFΦR4 unit to GFP in a site-specific manner. For comparison, we also generated a Tat-S-S-GFP conjugate in the same manner. Incubation of HEK293 cells in the presence of 1 μM cFΦR4-S-S-GFP resulted in time-dependent accumulation of green fluorescence inside the cells (Figure 7B). The fluorescence signal was diffuse and present throughout the entire cell volume, but with higher concentrations in the nucleus. Some of the cells contained small spots of intense green fluorescence (indicated by arrows in Figure 7B), which may represent endosomally sequestered cFΦR4-S-S-GFP or aggregated GFP inside the cell. As expected, untagged GFP was unable to enter cells, whereas Tat-S-S-GFP entered cells less efficiently than cFΦR4-S-S-GFP (Figure 7B); FACS analysis of HeLa cells treated with 1 μM protein revealed a 5.5-fold higher total intracellular fluorescence for the latter. Moreover, cells treated with Tat-S-S-GFP showed predominantly punctate fluorescence in the cell periphery with no detectable fluorescence in the nuclear region, suggesting that Tat-S-S-GFP is mostly entrapped in the endosomes, in agreement with previous reports.35 Thus, with a protein as cargo, cFΦR4 also has an efficiency substantially higher than that of Tat with regard to both initial uptake and endosomal escape. Attempts to test R9-S-S-GFP with cells failed because of precipitation of the conjugate.

Figure 7.

Figure 7

Open in a new tab

(A) Structures of CPP-S-S-GFP conjugates. (B) Live cell confocal images of HEK293 cells after treatment for 2 h with 1 μM GFP (I), Tat-S-S-GFP (II), or cFΦR4-S-S-GFP (III) and nuclear stain DRAQ5. All images were recorded in the same Z section.

To demonstrate the generality of cFΦR4 for protein delivery, we chose next to deliver a functional enzyme, the catalytic domain of PTP1B (amino acids 1–321), into the cell interior. To show that a noncleavable linkage is also compatible with our delivery method, we conjugated cFΦR4 to ybbR-tagged PTP1B via a thioether bond (cFΦR4-PTP1B) (Figure S3 of the Supporting Information). An in vitro assay using p-nitrophenyl phosphate as a substrate showed that addition of the cFΦR4 tag does not affect the catalytic activity of PTP1B (Table S2 of the Supporting Information). NIH 3T3 cells were incubated for 2 h in the presence of untagged PTP1B or cFΦR4-PTP1B, and their global pY protein levels were analyzed by anti-pY Western blotting (Figure 8A). Treatment of the cells with cFΦR4-PTP1B, but not untagged PTP1B, resulted in a concentration-dependent decrease in pY levels of most, but not all, proteins. The total cellular protein levels, as detected by Coomassie blue staining, were unchanged (Figure 8B), indicating that the observed decrease in pY levels was due to dephosphorylation of the pY proteins by cFΦR4-PTP1B and/or secondary effects caused by the introduction of cFΦR4-PTP1B (e.g., inactivation of cellular protein tyrosine kinases). Interestingly, different proteins exhibited varying dephosphorylation kinetics. Several proteins in the 150–200 kDa range were completely dephosphorylated upon the addition of 62 nM cFΦR4-PTP1B, whereas proteins of ∼80 kDa remained phosphorylated at 500 nM cFΦR4-PTP1B. The changes in the pY pattern are consistent with the broad substrate specificity of PTP1B77 and very similar to that caused by overexpression of PTP1B inside the cytosol of mammalian cells.78 Our results indicate that cFΦR4 is indeed able to deliver PTP1B into the interior of NIH 3T3 cells in the catalytically active form and to sufficient levels to dramatically perturb the cell signaling process. cFΦR4 thus provides a powerful tool for introducing other functional proteins, especially proteins that cannot be genetically expressed (e.g., toxic and chemically modified proteins), into mammalian cells for studying their cellular functions.

Figure 8.

Figure 8

Open in a new tab

(A) Western blot analysis of the global pY protein levels of NIH 3T3 cells after treatment with 0–500 nM PTP1B or cFΦR4-PTP1B (IB, anti-pY antibody 4G10). (B) The same samples as in panel A were analyzed by SDS–PAGE and Coomassie blue staining. M denotes molecular weight markers.

Stability and Cytotoxicity of cFΦR4

The relative stability of cFΦR4, R9, Tat, and Antp (Table 1, compounds 19–22, respectively) against proteolytic degradation was determined by incubating the CPPs in 25% human serum at 37 °C and following the disappearance of the full-length peptides by reversed-phase HPLC. The cationic tryptophan-containing peptide, Antp, was least stable among the four CPPs; it was degraded at a half-life of <20 min and was completely digested after 2 h (Figure 9A). R9 and Tat were slightly more stable than Antp, having half-lives of ∼30 min. In contrast, cFΦR4 was remarkably stable against serum proteases. There was <10% degradation after incubation for 6 h; after incubation for 24 h in the serum, >70% of cFΦR4 remained intact. Numerous other studies have also demonstrated that cyclization of peptides greatly increases their proteolytic stabilities.79 The potential cytotoxicity of cFΦR4 was assessed by MTT assays with five different human cell lines (HEK293, MCF-7, A549, H1650, and H1299). After incubation for 24 or 48 h with up to 50 μM cFΦR4, there was no significant growth inhibition for any of the cell lines (Figure 9B and Figure S8 of the Supporting Information). After 72 h, a slight growth inhibition (up to 20%) was observed at 50 μM (Figure S8 of the Supporting Information). Thus, cFΦR4 is relatively nontoxic to mammalian cells.

Figure 9.

Figure 9

Open in a new tab

(A) Comparison of the serum stability of cFΦR4, Tat, R9, and Antp. (B) Cytotoxicity of cFΦR4. The indicated cell lines were treated with DMSO (control) or 5 or 50 μM cFΦR4 for 24 h, and the percentage of live cells was determined by the MTT assay.

Conclusion

In this study, we demonstrate that cFΦR4 is effective for the exocyclic delivery of small-molecule, peptide, and protein cargos into the cytoplasm and nucleus of mammalian cells. By using a pCAP-containing peptide as the cargo or reporter, we show that cFΦR4 is 3.7–12-fold more efficient than R9, Tat, and Antp for cytoplasmic cargo delivery, making cFΦR4 one of the most active CPPs known to date. Although modification of polybasic CPPs such as addition of hydrophobic acyl groups has previously been reported to enhance cellular uptake by a similar magnitude,27 to the best of our knowledge, these previous studies have not established whether the enhanced uptake translates into a similar increase in the cytoplasmic CPP concentration (our attempt to directly compare cFΦR4 and the acylated CPPs was not successful, because the latter caused extensive cell death during our experiments). The pCAP-based reporter system described in this work should provide a simple, robust method for quantitatively assessing the cytoplasmic delivery efficiency of other CPPs. Several lines of evidence indicate that cFΦR4 enters cells through multiple endocytic mechanisms, including its failure to enter cells at 4 °C or in the presence of sodium azide, partial overlap between the fluorescence puncta of cFΦR4Rho and the fluid-phase endocytic marker dextranFITC, colocalization of cFΦR4Rho and endosomal proteins Rab5 and Rab7, and a decreased level of cFΦR4Dex uptake upon administration of endocytic inhibitors. The minimal effect of the PI3K inhibitor wortmannin and the Rab5 Q79L mutation on the cytoplasmic delivery of cFΦR4, in addition to the strong colocalization observed between cFΦR4 and Rab5+ endosomes, suggest that cFΦR4 escapes from early endosomes (Figure 10). In comparison, Tat has been demonstrated to enter cells through endocytosis and be released from late endosomes, while R9 escapes endosomes prior to Rab7 recruitment.42 Early endosomal release offers significant advantages, especially for peptide and protein cargos, because it minimizes cargo degradation by late endosomal and lysosomal proteases and denaturation caused by acidification during endosomal maturation. Indeed, both GFP and PTP1B delivered into the cytoplasm by cFΦR4 were in their folded, active forms, as evidenced by the green fluorescence and the ability to dephosphorylate intracellular pY proteins, respectively. Additionally, because of its more rigid structure, cFΦR4 is significantly more stable against proteolytic degradation than linear peptides, and because of its smaller size, cFΦR4 is less expensive to synthesize and potentially less likely to interfere with the cargo function. These properties make cFΦR4 a useful transporter for cytosolic delivery of small molecules to protein cargos. Direct protein delivery provides a useful research tool, e.g., for studying the cellular function of a protein, as it offers improved temporal control over DNA transfection and subsequent gene expression and allows delivery of chemically modified proteins and proteins whose overexpression causes toxicity. The ability of cFΦR4 to escape from early endosomes and its simple structure may also provide an excellent system for elucidating the mechanism of endosomal escape and the factors that influence the escape efficiency.

Figure 10.

Figure 10

Open in a new tab

Diagram showing the points along the endocytic pathway where cFΦR4, R9, and Tat escape into the cytoplasm and where specific inhibitors are proposed to function.

Acknowledgments

We thank F. Rivera-Molina, Y. Zhu, Dr. J.-Q. Wu, and Dr. S. Cole for their assistance with confocal microscopy, Dr. D. Bong and Z. Zhou for their assistance with dynamic light scattering analysis, and Dr. A. Schepartz for helpful discussions.

Supporting Information Available

Additional materials and methods for peptide synthesis, SUV preparation, FP assay, preparation of cFΦR4-PTP1B, image analysis, flow cytometry analysis, the serum stability assay, and the cytotoxicity assay. This material is available free of charge via the Internet at http://pubs.acs.org.

This work was supported by National Institutes of Health (NIH) Grants GM062820, GM74756, CA170741, and DE019667. J.R.L. gratefully acknowledges support from an NIH Chemistry-Biology Interface Training Program (T32GM067543).

The authors declare no competing financial interest.

Funding Statement

National Institutes of Health, United States

Supplementary Material

bi5004102_si_001.pdf (907.7KB, pdf)

References

  1. Frankel A. D.; Pabo C. O. (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55, 1189–1193. [DOI] [PubMed] [Google Scholar]
  2. Green M.; Loewenstein P. M. (1988) Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55, 1179–1188. [DOI] [PubMed] [Google Scholar]
  3. Langel Ü. (2011) Cell-penetrating peptides: Methods and protocols, p xv, Humana Press, New York. [Google Scholar]
  4. Schmidt N.; Mishra A.; Lai G. H.; Wong G. C. (2010) Arginine-rich cell-penetrating peptides. FEBS Lett. 584, 1806–1813. [DOI] [PubMed] [Google Scholar]
  5. Futaki S. (2005) Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv. Drug Delivery Rev. 57, 547–558. [DOI] [PubMed] [Google Scholar]
  6. Stewart K. M.; Horton K. L.; Kelley S. O. (2008) Cell-penetrating peptides as delivery vehicles for biology and medicine. Org. Biomol. Chem. 6, 2242–2255. [DOI] [PubMed] [Google Scholar]
  7. Deshayes S.; Morris M. C.; Divita G.; Heitz F. (2005) Cell-penetrating peptides: Tools for intracellular delivery of therapeutics. Cell. Mol. Life Sci. 62, 1839–1849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Goun E. A.; Pillow T. H.; Jones L. R.; Rothbard J. B.; Wender P. A. (2005) Molecular Transporters: Synthesis of oligoguanidinium transporters and their application to drug delivery and real-time imaging. ChemBioChem 7, 1497–1515. [DOI] [PubMed] [Google Scholar]
  9. Rothbard J. B.; Garlington S.; Lin Q.; Kirschberg T.; Kreider E.; McGrane P. L.; Wender P. A.; Khavari P. A. (2000) Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat. Med. 6, 1253–1257. [DOI] [PubMed] [Google Scholar]
  10. Nori A.; Jensen K. D.; Tijerina M.; Kopeckova P.; Kopecek J. (2003) Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells. Bioconjugate Chem. 14, 44–50. [DOI] [PubMed] [Google Scholar]
  11. Hoyer J.; Neundorf I. (2012) Peptide vectors for the nonviral delivery of nucleic acids. Acc. Chem. Res. 45, 1048–1056. [DOI] [PubMed] [Google Scholar]
  12. Eguchi A.; Akuta T.; Okuyama H.; Senda T.; Yokoi H.; Inokuchi H.; Fujita S.; Hayakawa T.; Takeda K.; Hasegawa M.; Nakanishi M. (2001) Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells. J. Biol. Chem. 276, 26204–26210. [DOI] [PubMed] [Google Scholar]
  13. Nakase I.; Akita H.; Kogure K.; Graslund A.; Langel U.; Harashima H.; Futaki S. (2012) Efficient Intracellular Delivery of Nucleic Acid Pharmaceuticals Using Cell-Penetrating Peptides. Acc. Chem. Res. 45, 1132–1139. [DOI] [PubMed] [Google Scholar]
  14. Andaloussi S. E.; Lehto T.; Mager I.; Rosenthal-Aizman K.; Oprea I. I.; Simonson O. E.; Sork H.; Ezzat K.; Copolovici D. M.; Kurrikoff K.; Viola J. R.; Zaghloul E. M.; Sillard R.; Johansson H. J.; Said Hassane F.; Guterstam P.; Suhorutsenko J.; Moreno P. M.; Oskolkov N.; Halldin J.; Tedebark U.; Metspalu A.; Lebleu B.; Lehtio J.; Smith C. I.; Langel U. (2011) Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res. 39, 3972–3987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jeong J. H.; Mok H.; Oh Y. K.; Park T. G. (2009) siRNA conjugate delivery systems. Bioconjugate Chem. 20, 5–14. [DOI] [PubMed] [Google Scholar]
  16. Muratovska A.; Eccles M. R. (2004) Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. 558, 63–68. [DOI] [PubMed] [Google Scholar]
  17. Wadia J. S.; Dowdy S. F. (2005) Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv. Drug Delivery Rev. 57, 579–596. [DOI] [PubMed] [Google Scholar]
  18. Pooga M.; Kut C.; Kihlmark M.; Hallbrink M.; Fernaeus S.; Raid R.; Land T.; Hallberg E.; Bartfai T.; Langel U. (2001) Cellular translocation of proteins by transportan. FASEB J. 15, 1451–1453. [DOI] [PubMed] [Google Scholar]
  19. Schwarze S. R.; Ho A.; Vocero-Akbani A.; Dowdy S. F. (1999) In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 285, 1569–1572. [DOI] [PubMed] [Google Scholar]
  20. Josephson L.; Tung C. H.; Moore A.; Weissleder R. (1999) High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjugate Chem. 10, 186–191. [DOI] [PubMed] [Google Scholar]
  21. Gupta B.; Levchenko T. S.; Torchilin V. P. (2005) Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Delivery Rev. 57, 637–651. [DOI] [PubMed] [Google Scholar]
  22. Liu J.; Zhang Q.; Remsen E. E.; Wooley K. L. (2001) Nanostructured materials designed for cell binding and transduction. Biomacromolecules 2, 362–368. [DOI] [PubMed] [Google Scholar]
  23. Saar K.; Lindgren M.; Hansen M.; Eiriksdottir E.; Jiang Y.; Rosenthal-Aizman K.; Sassian M.; Langel U. (2005) Cell-penetrating peptides: A comparative membrane toxicity study. Anal. Biochem. 345, 55–65. [DOI] [PubMed] [Google Scholar]
  24. Suhorutsenko J.; Oskolkov N.; Arukuusk P.; Kurrikoff K.; Eriste E.; Copolovici D. M.; Langel U. (2011) Cell-penetrating peptides, PepFects, show no evidence of toxicity and immunogenicity in vitro and in vivo. Bioconjugate Chem. 22, 2255–2262. [DOI] [PubMed] [Google Scholar]
  25. Rueping M.; Mahajan Y.; Sauer M.; Seebach D. (2002) Cellular uptake studies with β-peptides. ChemBioChem 3, 257–259. [DOI] [PubMed] [Google Scholar]
  26. Cooley C. B.; Trantow B. M.; Nederberg F.; Kiesewetter M. K.; Hedrick J. L.; Waymouth R. M.; Wender P. A. (2009) Oligocarbonate molecular transporters: Oligomerization-based syntheses and cell-penetrating studies. J. Am. Chem. Soc. 131, 16401–16403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Pham W.; Kircher M. F.; Weissleder R.; Tung C. H. (2004) Enhancing membrane permeability by fatty acylation of oligoarginine peptides. ChemBioChem 5, 1148–1151. [DOI] [PubMed] [Google Scholar]
  28. Herce H. D.; Garcia A. E. (2007) Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc. Natl. Acad. Sci. U.S.A. 104, 20805–20810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hirose H.; Takeuchi T.; Osakada H.; Pujals S.; Katayama S.; Nakase I.; Kobayashi S.; Haraguchi T.; Futaki S. (2012) Transient focal membrane deformation induced by arginine-rich peptides leads to their direct penetration into cells. Mol. Ther. 20, 984–993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Herce H. D.; Garcia A. E.; Litt J.; Kane R. S.; Martin P.; Enrigue N.; Rebolledo A.; Milesi V. (2009) Arginine-rich peptides destabilize the plasma membrane, consistent with a pore formation translocation mechanism of cell-penetrating peptides. Biophys. J. 97, 1917–1925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Palm-Apergi C.; Lorents A.; Padari K.; Pooga M.; Hallbrink M. (2009) The membrane repair response masks membrane disturbances caused by cell-penetrating peptide uptake. FASEB J. 23, 214–223. [DOI] [PubMed] [Google Scholar]
  32. Richard J. P.; Melikov K.; Brooks H.; Prevot P.; Lebleu B.; Chernomordik L. V. (2005) Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J. Biol. Chem. 280, 15300–15306. [DOI] [PubMed] [Google Scholar]
  33. Ferrari A.; Pellegrini V.; Arcangeli C.; Fittipaldi A.; Giacca M.; Beltram F. (2003) Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. Mol. Ther. 8, 284–294. [DOI] [PubMed] [Google Scholar]
  34. Fittipaldi A.; Ferrari A.; Zoppe M.; Arcangeli C.; Pellegrini V.; Beltram F.; Giacca M. (2003) Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J. Biol. Chem. 278, 34141–34149. [DOI] [PubMed] [Google Scholar]
  35. Kaplan I. M.; Wadia J. S.; Dowdy S. F. (2005) Cationic TAT peptide transduction domain enters cells by macropinocytosis. J. Controlled Release 102, 247–253. [DOI] [PubMed] [Google Scholar]
  36. Nakase I.; Tadokoro A.; Kawabata N.; Takeuchi T.; Katoh H.; Hiramoto K.; Negishi M.; Nomizu M.; Sugiura Y.; Futaki S. (2007) Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochemistry 46, 492–501. [DOI] [PubMed] [Google Scholar]
  37. Duchardt F.; Fotin-Mleczek M.; Schwarz H.; Fischer R.; Brock R. (2007) A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8, 848–866. [DOI] [PubMed] [Google Scholar]
  38. Mueller J.; Kretzschmar I.; Volkmer R.; Boisguerin P. (2008) Comparison of cellular uptake using 22 CPPs in 4 different cell lines. Bioconjugate Chem. 19, 2363–2374. [DOI] [PubMed] [Google Scholar]
  39. Maiolo J. R.; Ferrer M.; Ottinger E. A. (2005) Effects of cargo molecules on the cellular uptake of arginine-rich cell-penetrating peptides. Biochim. Biophys. Acta 1712, 161–172. [DOI] [PubMed] [Google Scholar]
  40. El-Sayed A.; Futaki S.; Harashima H. (2009) Delivery of macromolecules using arginine-rich cell-penetrating peptides: Ways to overcome endosomal entrapment. AAPS J. 11, 13–22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Varkouhi A. K.; Scholte M.; Storm G.; Haisma H. J. (2011) Endosomal escape pathways for delivery of biologicals. J. Controlled Release 151, 220–228. [DOI] [PubMed] [Google Scholar]
  42. Appelbaum J. S.; LaRochelle J. R.; Smith B. A.; Balkin D. M.; Holub J. M.; Schepartz A. (2012) Arginine topology controls escape of minimally cationic proteins from early endosomes to the cytoplasm. Chem. Biol. 19, 819–830. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Qian Z.; Liu T.; Liu Y. Y.; Briesewitz R.; Barrios A. M.; Jhiang S. M.; Pei D. (2013) Efficient delivery of cyclic peptides into mammalian cells with short sequence motifs. ACS Chem. Biol. 8, 423–431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Lattig-Tunnemann G.; Prinz M.; Hoffmann D.; Behlke J.; Palm-Apergi C.; Morano I.; Herce H. D.; Cardoso M. C. (2011) Backbone rigidity and static presentation of guanidinium groups increases cellular uptake of arginine-rich cell-penetrating peptides. Nat. Commun. 2, 453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Mandal D.; Nasrolahi Shirazi A.; Parang K. (2011) Cell-penetrating homochiral cyclic peptides as nuclear-targeting molecular transporters. Angew. Chem., Int. Ed. 50, 9633–9637. [DOI] [PubMed] [Google Scholar]
  46. Zhao K.; Choe U. J.; Kamei D. T.; Wong G. C. L. (2012) Enhanced activity of cyclic transporter sequences driven by phase behavior of peptide-lipid complexes. Soft Matter 8, 6430–6433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Lian W.; Upadhyaya P.; Rhodes C. A.; Liu Y.; Pei D. (2013) Screening bicyclic peptide libraries for protein-protein interaction inhibitor: Discovery of a tumor necrosis factor-α antagonist. J. Am. Chem. Soc. 135, 11990–11995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Mitra S.; Barrios A. M. (2005) Highly sensitive peptide-based probes for protein tyrosine phosphatase activity utilizing a fluorogenic mimic of phosphotyrosine. Bioorg. Med. Chem. Lett. 15, 5124–5145. [DOI] [PubMed] [Google Scholar]
  49. Stanford S. M.; Panchal R. G.; Walker L. M.; Wu D. J.; Falk M. D.; Mitra S.; Damle S. S.; Ruble D.; Kaltcheva T.; Zhang S.; Zhang Z. Y.; Bavari S.; Barrios A. M.; Bottini N. (2012) High-throughput screen using a single-cell tyrosine phosphatase assay reveals biologically active inhibitors of tyrosine phosphatase CD45. Proc. Natl. Acad. Sci. U.S.A. 109, 13972–13977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Yin J.; Straight P. D.; McLoughlin S. M.; Zhou Z.; Lin A. J.; Golan D. E.; Kelleher N. L.; Kolter R.; Walsh C. T. (2005) Genetically encoded short peptide tag for versatile protein labeling by Sfp phosphopantetheinyl transferase. Proc. Natl. Acad. Sci. U.S.A. 102, 15815–15820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Holub J. M.; LaRochelle J. R.; Appelbaum J. S.; Schepartz A. (2013) Improved assays for determining the cytosolic access of peptides, proteins, and their mimetics. Biochemistry 52, 9036–6046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Huotari J.; Helenius A. (2011) Endosome maturation. EMBO J. 30, 3481–3500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Rink J.; Ghigo E.; Kalaidzidis Y.; Zerial M. (2005) Rab conversion as a mechanism of progression from early to late endosomes. Cell 122, 735–749. [DOI] [PubMed] [Google Scholar]
  54. Yu P.; Liu B.; Kodadek T. (2005) A high-throughput assay for assessing the cell permeability of combinatorial libraries. Nat. Biotechnol. 23, 746–751. [DOI] [PubMed] [Google Scholar]
  55. Pratt W. B.; Toft D. O. (1997) Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev. 18, 306–360. [DOI] [PubMed] [Google Scholar]
  56. Picard D.; Yamamoto K. R. (1987) Two signals mediate hormone-dependent nuclear localization of the glucocorticoid receptor. EMBO J. 6, 3333–3340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Macia E.; Ehrlich M.; Massol R.; Boucrot E.; Brunner C.; Kirchhausen T. (2006) Dynasore, a cell-permeable inhibitor of dynamin. Dev. Cell 10, 839–850. [DOI] [PubMed] [Google Scholar]
  58. Koivusalo M.; Welch C.; Hayashi H.; Scott C. C.; Kim M.; Alexander T.; Touret N.; Hahn K. M.; Grinstein S. (2010) Amiloride inhibits macropinocytosis by lowering submembranous pH and preventing Rac1 and Cdc42 signaling. J. Cell Biol. 188, 547–563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Rodal S. K.; Skretting G.; Garred O.; Vilhardt F.; van Deurs B.; Sandvig K. (1999) Extraction of cholesterol with methyl-β-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol. Biol. Cell 10, 961–974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Yoshimori T.; Yamamoto A.; Moriyama Y.; Futai M.; Tashiro Y. (1991) Bafilomycin A1, a specific inhibitor of vacuolar-type H+-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J. Biol. Chem. 266, 17707–17712. [PubMed] [Google Scholar]
  61. Li G.; D’Souza-Schorey C.; Barbieri M. A.; Roberts R. L.; Klippel A.; Williams L. T.; Stahl P. D. (1995) Evidence for phophatidylinositol 3-kinase as a regulator of endocytosis via activation of Rab5. Proc. Natl. Acad. Sci. U.S.A. 92, 10207–10211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Stenmark H.; Parton R. G.; Steele-Mortimer O.; Lutcke A.; Gruenberg J.; Zerial M. (1994) Inhibition of rab5 GTPase activity stimulates membrane fusion in endocytosis. EMBO J. 13, 1287–1296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Rusnati M.; Tulipano G.; Spillmann D.; Tanghetti E.; Oreste P.; Zoppetti G.; Giacca M.; Presta M. (1999) Multiple interactions of HIV-1 Tat protein with size-defined heparin oligosaccharides. J. Biol. Chem. 274, 28198–28205. [DOI] [PubMed] [Google Scholar]
  64. Tyagi M.; Rusnati M.; Presta M.; Giacca M. (2001) Internalization of HIV-1 tat requires cell surface heparin sulfate proteoglycans. J. Biol. Chem. 276, 3254–3261. [DOI] [PubMed] [Google Scholar]
  65. Ziegler A.; Seelig J. (2004) Interaction of the protein transduction domain of HIV-1 TAT with heparan sulfate: Binding mechanism and thermodynamic parameters. Biophys. J. 86, 254–263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Goncalves E.; Kitas E.; Seelig J. (2005) Binding of oligoarginine to membrane lipids and heparan sulfate: Structural and thermodynamic characterization of a cell-penetrating peptide. Biochemistry 44, 2692–2702. [DOI] [PubMed] [Google Scholar]
  67. Ziegler A. (2008) Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and glycosaminoglycans. Adv. Drug Delivery Rev. 60, 580–597. [DOI] [PubMed] [Google Scholar]
  68. Alonso A.; Sasin J.; Bottini N.; Friedberg I.; Friedberg I.; Osterman A.; Godzik A.; Hunter T.; Dixon J.; Mustellin T. (2004) Protein tyrosine phosphatases in the human genome. Cell 117, 699–711. [DOI] [PubMed] [Google Scholar]
  69. Driggers E. M.; Hale S. P.; Lee J.; Terrett N. K. (2008) The exploration of macrocycles for drug discovery: An underexploited structural class. Nat. Rev. Drug Discovery 7, 608–624. [DOI] [PubMed] [Google Scholar]
  70. Marsault E.; Peterson M. L. (2011) Macrocycles are great cycles: Applications, opportunities, and challenges of synthetic macrocycles in drug discovery. J. Med. Chem. 54, 1961–2004. [DOI] [PubMed] [Google Scholar]
  71. Liu T.; Qian Z.; Xiao Q.; Pei D. (2011) High-throughput screening of one-bead-one-compound libraries: Identification of cyclic peptidyl inhibitors against calcineurin/NFAT interaction. ACS Comb. Sci. 13, 537–546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Dewan V.; Liu T.; Chen K. M.; Qian Z.; Xiao Y.; Kleiman L.; Mahasenan K. V.; Li C.; Matsuo H.; Pei D.; Musier-Forsyth K. (2012) Cyclic peptide inhibitors of HIV-1 capsid-human lysyl-tRNA synthetase interaction. ACS Chem. Biol. 7, 761–769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Wu X.; Upadhyaya P.; Villalona-Calero M. A.; Briesewitz R.; Pei D. (2013) Inhibition of Ras-effector interactions by cyclic peptides. Med. Chem. Commun. 4, 378–382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Kwon Y.-U.; Kodadek T. (2007) Quantative comparison of the telative cell permeability of cyclic and linear peptides. Chem. Biol. 14, 671–677. [DOI] [PubMed] [Google Scholar]
  75. Rezai T.; Yu B.; Millhauser G. L.; Jacobson M. P.; Lokey R. S. (2006) Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. J. Am. Chem. Soc. 128, 2510–2511. [DOI] [PubMed] [Google Scholar]
  76. Chatterjee J.; Gilon C.; Hoffman A.; Kessler H. (2008) N-Methylation of Peptides: A New Perspective in Medicinal Chemistry. Acc. Chem. Res. 41, 1331–1342. [DOI] [PubMed] [Google Scholar]
  77. Ren L.; Chen X.; Luechapanichkul R.; Selner N. G.; Meyer T. M.; Wavreille A. S.; Chan R.; Iorio C.; Zhou X.; Neel B. G.; Pei D. (2011) Substrate specificity of protein tyrosine phosphatases 1B, RPTPα, SHP-1, and SHP-2. Biochemistry 50, 2339–2356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. LaMontagne K. R. Jr.; Hannon G.; Tonks N. K. (1998) Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of Rat-1 fibroblasts and promotes differentiation of K562 cells. Proc. Natl. Acad. Sci. U.S.A. 95, 14094–14099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Nguyen L. T.; Chau J. K.; Perry N. A.; de Boer L.; Zaat S. A. J.; Vogel H. J. (2010) Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. PLoS One 5, e12684. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

bi5004102_si_001.pdf (907.7KB, pdf)

Articles from Biochemistry are provided here courtesy of American Chemical Society

RESOURCES